DOJ Files 300-Page Lawsuit in Chicago Against Walgreens for Unlawful Opioid Prescriptions Since 2012
Jan 18, 2025, 02:17 AM
The U.S. Department of Justice has filed a 300-page lawsuit against Walgreens in the U.S. District Court in Chicago, accusing the pharmacy chain of filling millions of unlawful prescriptions for controlled substances, including opioids, from August 2012 to the present. The lawsuit alleges that Walgreens pharmacists filled prescriptions with clear red flags indicating they were likely unlawful, and that the company pressured its pharmacists to fill prescriptions quickly without verifying their validity. Walgreens is also accused of ignoring evidence from its own pharmacists and internal data that its stores were dispensing unlawful prescriptions. The company, which operates over 8,000 locations, has responded by stating it stands behind its pharmacists, who it claims fill legitimate prescriptions in accordance with all applicable laws and regulations. Walgreens is seeking court clarification on the responsibilities of pharmacies and pharmacists, arguing against what it calls arbitrary government rules. Following the lawsuit announcement, Walgreens stock sank. The DOJ filed a similar lawsuit against CVS in December.
View original story
Settlement • 25%
Trial verdict in favor of DOJ • 25%
Trial verdict in favor of Walgreens • 25%
Case dismissed • 25%
Ongoing litigation • 25%
Other outcome • 25%
Case dismissed • 25%
CVS settles • 25%
CVS found liable • 25%
CVS found guilty • 25%
CVS settles • 25%
Case dismissed • 25%
CVS found liable • 25%
CVS not liable • 25%
More than $5 billion • 25%
No penalty • 25%
$1 billion to $5 billion • 25%
Less than $1 billion • 25%
Case dismissed • 25%
CVS not found liable • 25%
CVS found liable • 25%
Settlement reached • 25%
Sale abandoned • 25%
Sale to another party • 25%
No sale • 25%
Sale completed • 25%
Walgreens • 25%
Rite Aid • 25%
Walmart • 25%
None of the above • 25%
Other • 25%
Rite Aid • 25%
Walmart • 25%
CVS • 25%
No change in market share • 25%
Increased market share • 25%
Uncertain impact • 25%
Decreased market share • 25%